Revised SPC: Dupixent (dupilumab) solution for injection in pre-filled syringe- all strengths

SPC revised to state that the safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent with the safety profile observed in pivotal asthma studies for up to 52 weeks of treatment.

Source:

electronic Medicines compendium